Our group programming now more closely mirrors what our clients have told us regarding the issues with which they struggle that have led them to relapsing
in the past.
Compatible clinical disease descriptions have been documented since the time of Hippocrates; however, the term relapsing
fever was first used by David Craigie to describe an outbreak of the disease in Edinburgh in 1843 (1).
Headquartered in Cambridge, MA, the company's revenues are generated from international sales of AVONEX (Interferon beta-1a) for treatment of relapsing
forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products.
In the Phase III TEMSO trial, AUBAGIO 14 mg significantly reduced the annual relapse rate and the time to disability progression at two years versus placebo in patients with relapsing
forms of multiple sclerosis.
Physicians should be alert for relapsing
fever in travelers, and this diagnosis should be considered in febrile patients from disease-endemic regions.
Although gross findings are nonspecific, relapsing
polychondritis is characterized by an overall thickening of the cartilage of the ear, nose, epiglottis, and cricoid and tracheal rings.
patients, however, craving diminished over time with the drug but not with placebo.
In a 24-month study of 149 patients, treatment had a significant impact on "prolonging time to first treated relapse and on delaying disability progression" in patients with secondary progressive or progressive relapsing
MS, and a significant reduction in the number of treated relapses and new MS lesions on magnetic resonance imaging, the company said.
M2 EQUITYBITES-September 13, 2012-Genzymea[euro](tm)s AUBAGIO approved by FDA as once-daily, oral treatment for relapsing
Multiple Sclerosis(C)2012 M2 COMMUNICATIONS http://www.m2.com
M2 PHARMA-September 13, 2012-Genzyme receives FDA approval for AUBAGIO (teriflunomide) for relapsing
multiple sclerosis(C)2012 M2 COMMUNICATIONS
Of greater concern are six cases including five from the 12 months MB-MDT treated group (21%) and one RO treated patient who were relapsing
for the second time.
Although more relapsing
patients reported using sunblock after the removal of their tumor than controls--91% vs.
In November 2004, the FDA granted accelerated approval of Tysabri (natalizumab) for treatment of relapsing
forms of MS, creating a new treatment option.
miyamotoi, a sister species to the relapsing
fever group of spirochetes (2,3).